Skip to main content
. 2020 Oct 20;11(10):879. doi: 10.1038/s41419-020-03101-9

Fig. 5. IPO13 implicates in the viability of NSCLCs by downregulation of hTERT.

Fig. 5

A, B Downregulation of hTERT expression at protein and mRNA levels in H1299 and A549 cell lines treated with IPO13 siRNA for 48 h. C MTT assay used to detect cell viability in (H1299 and A549) cells transfected with IPO13 siRNA (n = 3, **P < 0.01, ***P < 0.001). D Cell proliferation assay in H1299 and A549 cells upon stable knockdown of IPO13 then overexpresses hTERT (n = 3, **P < 0.01, ***P < 0.001, ****P < 0.0001). E Pull-down assay conducted in the nuclear extract of H1299 and A549 cells to evaluate the binding of RFPL3 to hTERT promoter (−378 to +60). NSP, nonspecific. F The interaction between RFPL3 and hTERT promoter (−160 to +60) in H1299 cells was validated by ChIP assay. G A schematic model of the nuclear transport mechanism of RFPL3. Importin 13 mediates the nuclear transport of RFPL3 by recognizing an active NLS at the C terminal. RFPL3 nuclear translocation, in coordination with CBP’s transcriptional co-activation, promotes hTERT transcription. NPC nuclear pore complex, TF transcription factor, CBP CREB-binding protein.